Position in ANNX
as of Mar 31, 2026
· filed Apr 16, 2026
Position Value
$237,666
+$22,308 QoQ
Shares Held
42,900
0.0% QoQ
Ownership
0.021%
of shares outstanding
% of Portfolio
0.09%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2023
11 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in ANNX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Allegheny Financial Group holds $1,531,910 across 6 Biotechnology names. ANNX ranks #3 (15.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
2,018 | $901,117 | |
| 2 | INSM |
INSMED Inc
|
1,479 | $241,846 | |
| 3 | ANNX |
Annexon, Inc.
This page
|
42,900 | $237,666 | |
| 4 | PGEN |
Precigen, Inc.
|
17,065 | $66,041 | |
| 5 | TSHA |
Taysha Gene Therapies, Inc.
|
12,000 | $53,640 | |
| 6 | LCTX |
Lineage Cell Therapeutics, Inc.
|
20,000 | $31,600 |
All Filings in ANNX
Export CSV
11 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $237,666 | 42,900 | Shares | Sole | 2026-04-16 | |
| 2025-12-31 | $215,358 | 42,900 | Shares | Sole | 2026-02-02 | |
| 2025-09-30 | $130,845 | 42,900 | Shares | Sole | 2025-11-06 | |
| 2025-06-30 | $102,960 | 42,900 | Shares | Sole | 2025-08-13 | |
| 2025-03-31 | $48,636 | 25,200 | Shares | Sole | 2025-05-13 | |
| 2024-12-31 | $129,276 | 25,200 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $149,184 | 25,200 | Shares | Sole | 2024-11-14 | |
| 2024-06-30 | $123,480 | 25,200 | Shares | Sole | 2024-08-01 | |
| 2024-03-31 | $155,589 | 21,700 | Shares | Sole | 2024-05-07 | |
| 2023-12-31 | $98,518 | 21,700 | Shares | Sole | 2024-02-08 | |
| 2023-09-30 | $51,212 | 21,700 | Shares | Sole | 2023-11-14 | |
| No filing history on record for this holder in this stock. | ||||||